Bevacizumab (Avastin) is an antiangiogenic humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), which by normalization of tumor vasculature can improve drug delivery to the tumor (Cunningham et al., 2010). This evidence concerns the gene VEGFA and neoplasm.